|
|
Post by jammnott on Aug 5, 2014 22:03:08 GMT -5
Thanks for the informative post. The research is much appreciated.
As mnkd moves forward it will be interesting to see the supply chain grow. This is a great start, but the risk inherent in global business means we have more suppliers coming on board in the following months. I speculate this news was chosen for purpose by Mannkind to throw investors a bone until announcements of more substance are able to be made public, as it may be the first supplier of many. I think Al Mann and team will continue to craft their PR machine with language, emphasis and timing that maximizes the impact of these announcements. I look forward to the day when we hear about this type of story, and it's just the company's day to day. Tomorrow (actually rest of week) will be an interesting day to gauge investor sentiment and the resolve of the shorts have. For now, I'm just glad the silence is broken. Although this stock is a current source of some anxiety, I have to admit the news rollout is going to be as fun as the price movement. GLTA
|
|
|
|
Post by babaoriley on Aug 5, 2014 23:42:14 GMT -5
That was brought up by I believe Matt. They weren't sure if the FDA would let them use any or all of it. I never heard a result from that concern. But we hadn't heard anything til today. I'm about 99% sure on this. That stuff will be sold to the Ruskies! |
|
|
|
Post by babaoriley on Aug 5, 2014 23:51:07 GMT -5
"MannKind has agreed to purchase annual minimum quantities of Insulin under the Supply Agreement of an aggregate of approximately €120.1 million in calendar years 2015 through 2019." Could be read either way - per year or aggregate. If it were aggregate they should have said "through 2019 beginning in calendar year 2015" If two sentences contiguous sentences are quoted, rather than one, you have, "MannKind has agreed to purchase annual minimum quantities of Insulin under the Supply Agreement of an aggregate of approximately €120.1 million in calendar years 2015 through 2019. MannKind may request to purchase additional quantities of Insulin over such annual minimum quantities. " Emphasis added by baba. The first sentence is as clearly ambiguous, as clearly ambiguous is oxymoronic. The use of the word "aggregate" in the first sentence, tips the scales toward thinking it means "aggregate" over the initial term of the contract. How someone who is supposed to write clearly, wrote this, is, shall we say, surprising. The implication, if not the clear meaning, of the second sentence, however, tips it back over to approximately 120 million Euros per year. Makes quite a difference, doesn't it. While we might not get many answers on Monday, this one we'll get if someone asks (don't know if analysts will be there asking questions after the presentation, I assume so). AF, Shkreli, OPC, others of their ilk. |
|
|
|
Post by joeypotsandpans on Aug 6, 2014 12:39:35 GMT -5
It means that there will be a need for insulin to be manufactured for use in Afrezza. Interesting that it's a French company and it's being paid in Euros. Could there be a Sanofi connection? Looks like we have more questions that will be answered next Monday if not sooner. Could mean absolutely nothing or could mean a lot but fun fodder for speculation in any case: Synta Pharmaceuticals, Inc. (Nasdaq: SNTA) announced that Anne Whitaker will join the Company as President, Chief Executive Officer and a member of the Company’s Board of Directors effective September 2, 2014. Ms. Whitaker has more than 20 years of experience in the pharmaceutical industry, principally at GlaxoSmithKline and Sanofi (NYSE: SNY) including, most recently, the role of President, North America Pharmaceuticals, at Sanofi.
As President, North America Pharmaceuticals, at Sanofi, Ms. Whitaker oversaw all pharmaceutical and consumer healthcare operations within the region, including the Diabetes, Oncology, Cardiovascular and other Patient Centered Units Wonder who her replacement is and why she left that post to go to an unproven smaller entity, on the other hand maybe Synta has some promising pipeline items that she likes...who knows but the timing is a little bit curious just the same....like I said, just some fun speculative food for thought on a slow wednesday  |
|
|
|
Post by mdcenter61 on Aug 6, 2014 13:17:26 GMT -5
That was brought up by I believe Matt. They weren't sure if the FDA would let them use any or all of it. I never heard a result from that concern. But we hadn't heard anything til today. I'm about 99% sure on this. That stuff will be sold to the Ruskies!
I was kind of assuming that the old insulin would be sold to the Chinese since they sold us tainted baby formula and rotten meat!
|
|
|
|
Post by ashiwi on Aug 6, 2014 14:52:48 GMT -5
I would not be surprised to see a smaller pharma company become MNKD's partner. MNKD wants the partner to have Afrezza as their priority. Another BP company may put Afrezza on the back burner. A second tier pharma that has the resources to market Afrezza and ultimately Technosphere could turn into a larger top tier pharma within a couple of years. While a "no name" pharma partner may initially get a knee jerk reaction by shorts who knock the stock down, it may actually turn out just fine in the big picture.
|
|
|
|
Post by dreamboatcruise on Aug 6, 2014 17:39:20 GMT -5
I would not be surprised to see a smaller pharma company become MNKD's partner. MNKD wants the partner to have Afrezza as their priority. Another BP company may put Afrezza on the back burner. A second tier pharma that has the resources to market Afrezza and ultimately Technosphere could turn into a larger top tier pharma within a couple of years. While a "no name" pharma partner may initially get a knee jerk reaction by shorts who knock the stock down, it may actually turn out just fine in the big picture. That would not be good for those of us with short term out of the money call options... which is why that is only a slice of my total position. |
|
|
|
Post by 4allthemarbles on Aug 6, 2014 21:10:52 GMT -5
The first sentence is as clearly ambiguous, as clearly ambiguous is oxymoronic. The use of the word "aggregate" in the first sentence, tips the scales toward thinking it means "aggregate" over the initial term of the contract. How someone who is supposed to write clearly, wrote this, is, shall we say, surprising. The implication, if not the clear meaning, of the second sentence, however, tips it back over to approximately 120 million Euros per year. Makes quite a difference, doesn't it. While we might not get many answers on Monday, this one we'll get if someone asks (don't know if analysts will be there asking questions after the presentation, I assume so). AF, Shkreli, OPC, others of their ilk. That last part there was interesting... |
|
